State AGs Sue DEA Over Schedule III Cannabis Rescheduling Order

Coalition Challenges DEA Final Rule in Federal Court

State attorneys general filed suit in federal appellate court May 29, 2026, seeking to vacate DEA's Schedule III cannabis rescheduling order. The complaint names the DEA and Attorney General as defendants. It invokes the Administrative Procedure Act's judicial review provisions at 5 U.S.C. § 702. The multi-state coalition argues the final rule violates the Controlled Substances Act's eight-factor analysis required under 21 U.S.C. § 811(c).

The lawsuit arrives three weeks after DEA published its final rescheduling rule in the Federal Register. The rule took effect May 15, 2026, moving cannabis to Schedule III alongside ketamine and anabolic steroids. Oral arguments are expected in the Fourth Quarter 2026.

Petitioners Claim Rescheduling Undermines State Enforcement

The complaint argues Schedule III classification creates enforcement conflicts between federal medical cannabis regulations and existing state prohibition frameworks. Attorneys general from states without medical cannabis programs contend the rescheduling order preempts state authority to maintain stricter controlled substance schedules. They cite the Controlled Substances Act's cooperative federalism structure at 21 U.S.C. § 903, which permits states to impose more restrictive controls than federal law.

Petitioners also challenge DEA's reliance on the Department of Health and Human Services' August 2024 scheduling recommendation. The complaint alleges DEA failed to conduct an independent abuse-potential analysis as required by statute. According to the filing, the agency adopted HHS's findings without addressing public comments submitted during the 60-day notice period.

Financial and Operational Stakes for Cannabis Industry

The lawsuit injects uncertainty into the cannabis industry's anticipated tax relief under Internal Revenue Code § 280E. Schedule III status permits businesses to deduct ordinary operating expenses. That's a change projected to save multi-state operators $1.2 billion to $1.8 billion annually. A successful legal challenge would preserve the current tax treatment, which limits deductions to cost of goods sold.

MSOs including Curaleaf, Trulieve, and Green Thumb Industries have disclosed the Schedule III assumption in recent SEC filings. Share prices for the top five publicly traded operators declined an average 4.2% in after-hours trading May 29 following news of the lawsuit. Institutional investors are now pricing in litigation risk that could delay or reverse the rescheduling order.

Procedural Path and Timeline for Judicial Review

The case will proceed under the Administrative Procedure Act's arbitrary-and-capricious standard at 5 U.S.C. § 706(2)(A). Federal appellate courts have exclusive jurisdiction over challenges to DEA scheduling decisions under 21 U.S.C. § 877. The government has 60 days from the filing date to submit the administrative record supporting the final rule.

Legal observers expect the court to schedule oral arguments in October or November 2026. A panel decision could arrive in First Quarter 2027, with potential en banc review or Supreme Court petitions extending the timeline into 2028. For context on the underlying rescheduling process, see the CannIntel topic hub on DEA Cannabis Rescheduling.

What Industry Operators Should Monitor

Cannabis businesses should track three procedural milestones: the government's administrative record filing deadline (July 28, 2026), the court's briefing schedule order, and any motions for stay of the final rule pending review. A stay would suspend Schedule III status. It would reinstate Schedule I tax treatment during litigation. Companies relying on 280E relief for 2026 tax planning face material uncertainty if the court grants interim relief to petitioners.

State-level operators in plaintiff states may also face enforcement guidance changes. Attorneys general could issue advisories clarifying that state law enforcement won't recognize federal Schedule III status during pending litigation. That posture would preserve state-level felony penalties for cultivation and distribution in non-medical states.